

Medical Policy

Subject: ~~Ovarian and Internal Iliac~~-Vein Embolization as a Treatment ~~of~~for Pelvic Congestion Syndrome and Varicocele
Document #: SURG.00062
Status: Revisewed
Publish Date: 12/16/2020
Last Review Date: 11/02/0520/2020

Description/Scope

This document addresses ovarian and internal iliac vein embolization as a treatment for pelvic congestion syndrome (PCS) in women, and percutaneous testicular vein embolization for varicocele in men.

PCS, which is also referred to as pelvic venous incompetence (PVI), is a condition involving chronic pelvic pain (CPP) which is non-cyclic and of variable location and intensity. The CPP is usually aggravated by prolonged standing. The underlying etiology is thought to be related to varices of the ovarian veins, leading to pelvic congestion. As there are many etiologies for CPP, PCS is often a diagnosis of exclusion, when varices are identified with the identification of varices-using a variety of imaging methods, such as magnetic resonance imaging (MRI), computed tomography (CT) scanning or contrast venography. For those who do not respond to medical therapy with analgesics, embolization therapy of the ovarian and internal iliac veins has been proposed.

In men, testicular varicocele is a condition in which high hydrostatic pressure in the testicular veins (also called the spermatic veins) is thought to cause discomfort, pain and reduced fertility. Percutaneous embolization therapy has been used to treat varicocele as an alternative to surgical ligation (varicocelectomy) to improve symptoms, sperm count and sperm motility.

Position Statement

Investigational and Not Medically Necessary:

Embolization of the ovarian vein and internal iliac veins is considered **investigational and not medically necessary** as a treatment of pelvic congestion syndrome.

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

~~Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.~~

~~No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.~~

Ovarian and Internal Iliac Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele

Embolization of the testicular (spermatic) veins is considered **investigational and not medically necessary** as a treatment of testicular varicocele.

Rationale

The literature regarding the clinical outcomes for embolization therapy for treatment of pelvic congestion syndrome (PCS) is limited to primarily case series and one randomized comparative trial. Several older small case series report pain relief in 50-80% of women (Cordis, 1998; Sichlau, 1994; Tarazov, 1997). In 2013, 5-year results were reported for a prospective, single center case series of 202 women suffering from chronic pelvic pain (CPP) who were being treated for lower limb varices. Inclusion criteria were: lower limb varices and CPP of greater than 6 month duration; greater than 6 mm pelvic venous caliber on ultrasonography; and venous reflux or presence of communicating veins. Both ovarian and hypogastric veins were targeted for embolization. Pain level was assessed before and after embolotherapy and during follow-up using a visual analog scale (VAS). Technical and clinical success and recurrence of leg varices were studied. The study subjects completed a quality questionnaire, and clinical follow-up was performed at 1, 3, and 6 months and every year for 5 years. A total of 179 of 202 women (89%) completed the 5-year follow-up. The primary outcomes were pain improvement and individual post-procedure satisfaction. At baseline, the mean VAS was 7.34 (standard deviation [SD]: 0.7) and at 5 years the mean VAS was 0.78 (SD: 1.2). The decrease in the VAS score over time was statistically significant ($p < 0.0001$). Mean individual satisfaction scores were 7.39 (standard deviation [SD]: 1.5) on a 0 to 9 scale. There were 4 cases of coil migration (2%), which were considered to be a major complication; also groin hematoma occurred in 6 subjects. Post-procedure abdominal pain was reported in 23 subjects, and 24 subjects (12.5%) experienced recurrence of their leg varices within the follow-up period. Notably, this study was limited by the lack of a control group for clinical outcomes comparison and no clearly defined diagnostic criteria for use in trial subject selection (Laborda, 2013).

Additional small retrospective case series and single center chart reviews have reported favorable short-term outcomes (averaging 12-24 months) for embolization therapy related to VAS scores and symptomatic improvements. However, some investigators acknowledge difficulty in assessing subsequent recurrence rates, due to complexities associated with the pathophysiology of venous reflux disease and ongoing debate around the most effective embolic materials and techniques, as well as uncertainties about the most appropriate candidate selection (Hocquelet, 2014; Nasser, 2014).

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Ovarian and Internal Iliac Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele

Additional case series include Venbrux and colleagues who performed bilateral ovarian vein embolization therapy on 56 women, followed 3 to 10 weeks later by embolization of the internal iliac veins. The procedures were considered a technical success in all women, although in 2 women the coils inadvertently migrated to the pulmonary circulation where they were retrieved without incident. Recurrences of varices were noted in 3 women. In terms of pain control, the mean VAS score fell from 7.8 to 2.7 over a 12-month period (Venbrux, 2002).

In another case series of 41 women who underwent ovarian vein embolization, Maleux and colleagues (2000) reported a technical success rate of 98%. Partial or complete pain relief was reported by 68.3% of women. However, there was no formal assessment of pain prior to the procedure.

Chung compared the efficacy of embolization (n=52) to that of hysterectomy and bilateral oophorectomy (n=27) or hysterectomy and unilateral oophorectomy (n=27). Women were also stratified according to stress scores into three subgroups with normal, moderate-high and very high stress levels. A significant improvement in pain symptoms was observed in the three treatment groups. Women with normal to moderate-high stress levels who received embolization experienced superior symptom relief, compared to women who underwent hysterectomy with unilateral or bilateral oophorectomy. However, women with very high stress levels did not derive as much treatment benefit as women with normal to moderate-high stress levels (Chung, 2003).

Kim reported outcomes of internal iliac embolotherapy for chronic pelvic pain caused by ovarian and pelvic varices from 1998 to 2003. A total of 97 women completed long-term follow-up (mean 45 months \pm 18). Long-term follow-up showed that 83% of these women exhibited clinical improvement, 13% had no significant change, and 4% exhibited worsened condition (Kim, 2006).

Kwon reported findings for 67 women who underwent ovarian vein coil embolization. Evaluation after coil embolization was performed within 3-6 months (n=3), 6 months to 1 year (n=7), 1-2 years (n=13), 2-3 years (n=7), 3-4 years (n=7), 4-5 years (n=13), or 5-6 years (n=17). Outcome analysis showed 82% (55/67) experienced pain reduction after coil embolization, were satisfied with the procedure, and did not pursue any further treatment. Twelve women (18%, 12/67) responded that their pain level had not changed, or had become more severe; 9 women were treated surgically, and the remaining 3 women remained under continuous drug therapy (Kwon, 2007).

In a 2005 Cochrane review, *Interventions for Treating Chronic Pelvic Pain in Women*, Stones and colleagues found that there is a "Very limited range of interventions that have been tested for the treatment of women with chronic

[This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.](#)

~~Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.~~

~~No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.~~

Ovarian and Internal Iliac Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele

pelvic pain.” They concluded that, “Studies are currently needed to include trials of radiological embolization versus surgery for pelvic congestion” (Stones, 2005).

In a review, Smith discussed the current treatments for PCS, citing that the most common treatments used currently involve the embolization of pelvic and ovarian veins. Published outcomes of this treatment are available in a limited number of clinical series, usually with fairly short follow-up periods. The major complication of this treatment is migration of the materials (for example, e.g. coils) used to occlude veins. The longest duration of follow-up currently reported is 5 years. There is insufficient clinical evidence to support the use of embolization (embolotherapy) in the management of PCS (Smith, 2012).

Black commented on the paucity and quality of evidence supporting embolization treatment for PCS. In their publication, the authors outlined the research and reporting standards required to determine clinical efficacy of embolization for the treatment of PCS. The authors further proposed using pelvic venous insufficiency (PVI) to describe PCS because PVI is more specific to the pathophysiology and anatomy involved with compromised pelvic venous flow (Black, 2010).

A systematic review was conducted using 20 case series (total n=1081) of vein embolization for PCS. There were no randomized trials, and only one study included a control group. The immediate technical success rate in the occlusion of the affected veins was 99%, and 17 studies reported at 1- to 3- months for a total of 641 subjects. Results were reported as moderate to significant short-term, symptomatic relief in 88.1%, and 11.9% reported little or no relief. The total follow-up data varied between 7.3 months and 5 years. The authors concluded that in late follow-up, 86.6% reported relief of PCS symptoms and 13.6% experienced little or no relief (Maymoud, 2016).

Percutaneous embolization for gonadal venous insufficiency and varicocele in males has very limited evidence demonstrating safety and efficacy as compared to surgical repair. In 2018, a systematic review was performed to assess clinical outcomes for embolization treatment with different embolic materials for the management of testicular varicoceles. Study methodological quality was also analyzed. A total of 23 retrospective and 7 prospective clinical studies were included with a total of 3505 individuals. Although the technical success rates appeared high (above 90%) for all embolic materials used without significant differences, recurrence rates varied. Use of glue appeared to have the lowest recurrence rates, and sclerosant agents alone showed the highest rates. Recurrence rates were 4.2% for glue (11-3.08%; SD: 5.9) and 11.03% for sclerosants alone (18.8-5.15%; SD: 6.06) within an average follow-up period of 16.13 and 25.48 months respectively. Coils alone (n=898) had an average recurrence rate of 9.1% (17.8-1.4%; SD: 5.79) with a mean follow-up of 39.3 months. After an average of 12

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Ovarian and Internal Iliac Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele

months, the addition of sclerosants (n=1628) as an adjunct to coils did not improve recurrence rates (8.44%, 16.5-5.1%; SD: 3.4). At 1 year, glue appeared to be the most effective in preventing recurrence with coils being the second most effective. No differences were reported regarding the safety profile of the various embolic materials (Makris, 2018).

In 2014, the Practice Committee of the American Society for Reproductive Medicine, in conjunction with the Society for Male Reproduction and Urology, issued an updated opinion report on varicocele and infertility. This document discusses the evaluation and management of varicoceles in the male partners of infertile couples and provided the following:

None of these methods (surgical repair and percutaneous embolization) has proven superior to the other in its ability to improve fertility, although there are differences in recurrence rates...Results are variable and depend on the experience and skill of the interventional radiologist performing the procedure.

To summarize the current state of the published evidence, randomized studies are needed to determine whether embolization of the internal iliac or gonadal veins is an effective treatment for PCS or male varicocele. Given that no randomized trials have been performed in this area, the safety and effectiveness of vein embolization as a treatment for PCS or gonadal venous insufficiency (varicocele) in males cannot be reliably distinguished from other management approaches, including medical therapy or watchful waiting.

Background/Overview

PCS is often associated with dyspareunia and postcoital pain and typically affects young multiparous women. The underlying etiology is thought to be related to varices of the ovarian veins, leading to pelvic congestion. Approximately 10-15% of women may have pelvic varicose veins but not all will have symptoms. As there are many etiologies of CPP, PCS is often a diagnosis of exclusion, that is confirmed when other conditions have been ruled-out. The presence of pelvic varices associated with the syndrome may be identified using a variety of imaging methods, such as MRI, CT scanning or contrast venography.

For those who fail medical therapy (for example, analgesics, vasoconstrictors and hormonal therapies), surgical ligation of the ovarian vein may be considered. More recently, catheter-based embolization therapy of the ovarian and internal iliac veins has been proposed. Catheter-based therapies may be performed on an inpatient or outpatient. [This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.](#)

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Ovarian and Internal Iliac Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele

basis depending on the veins that are accessed and the technique that is used. Ovarian and internal iliac vein embolization is a therapy used to block blood flow to the veins that are causing pelvic congestion. It is performed by accessing the venous system via a catheter and injecting or deploying an inert material (for example, coils, solutions, plugs) to obstruct the affected veins. The embolization procedure may require multiple sessions. For example, one method involves use of gel foam and coils for embolization of the ovarian vein(s). This may be followed 3 to 10 weeks later by embolization of the internal iliac veins to reduce the risk of recurrence. Occasionally, the coils may migrate to another internal organ system, such as the pulmonary circulation, necessitating a retrieval procedure.

Definitions

Dysmenorrhea: Recurrent pelvic pain associated with menses and described as a painful cramping sensation in the lower abdomen, often accompanied by other symptoms, such as sweating, tachycardia, headaches, nausea, vomiting, diarrhea, and tremulousness. Primary dysmenorrhea begins at or shortly after menarche and is usually not accompanied by pelvic pathologic conditions. Secondary dysmenorrhea arises later in life and is usually associated with other pelvic conditions.

Dyspareunia: This term refers to painful sexual intercourse, due to medical or psychological causes. The symptom is significantly more common in women than in men, affecting up to one-fifth of women at some point in their lives. An extreme form, in which the woman's pelvic floor musculature contracts involuntarily, is termed vaginismus.

Embolization: A procedure in which targeted blood vessels are obstructed by delivering inert material (for example, coils, gels, foam) into the circulatory system.

Multiparous: The clinical term used for women with a history of one or more previous live births.

Pelvic congestion syndrome (PCS): A syndrome involving venous congestion and chronic pelvic pain that is generally associated with the veins in the pelvic area (for example, the ovarian veins).

Varices: Enlarged or twisted blood vessels.

Varicocele: A condition in which the testicular veins are enlarged within the scrotum caused by dilatation of the pampiniform plexus of spermatic veins and blood pooling. This condition results from incompetence of blood
This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Ovarian and Internal Iliac Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele

vessel leaflets, which leads to retrograde blood flow and increased pressure in the scrotal venous complex. This can result in testicular atrophy and decreased sperm quantity.

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

When services are Investigational and Not Medically Necessary:

CPT

37241 Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (eg, congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles)

ICD-10 Procedure

- [06L03DZ](#) [Occlusion of inferior vena cava with intraluminal device, percutaneous approach \[includes right ovarian vein, right testicular vein\]](#)
- [06L04DZ](#) [Occlusion of inferior vena cava with intraluminal device, percutaneous endoscopic approach \[includes right ovarian vein, right testicular vein\]](#)
- [06LB3DZ](#) [Occlusion of left renal vein with intraluminal device, percutaneous approach \[includes left ovarian vein, left testicular vein\]](#)
- [06LB4DZ](#) [Occlusion of left renal vein with intraluminal device, percutaneous endoscopic approach \[includes left ovarian vein, left testicular vein\]](#)
- [06LH3DZ](#) [Occlusion of right hypogastric vein with intraluminal device, percutaneous approach \[includes internal iliac vein\]](#)
- [06LH4DZ](#) [Occlusion of right hypogastric vein with intraluminal device, percutaneous endoscopic approach \[includes internal iliac vein\]](#)
- 06LY3DZ Occlusion of lower vein with intraluminal device, percutaneous approach
- 06LY4DZ Occlusion of lower vein with intraluminal device, percutaneous endoscopic approach

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

~~Ovarian and Internal Iliac~~ Vein Embolization as a Treatment ~~for~~ Pelvic Congestion Syndrome and Varicocele

ICD-10 Diagnosis

I86.1	Scrotal varices (varicocele)
I86.2	Pelvic varices [when indicated as ovarian and internal iliac vein varices]
I87.2	Venous insufficiency [when specified as gonadal or pelvic venous insufficiency]
N94.89	Other specified conditions associated with female genital organs and menstrual cycle [when indicated as chronic pelvic pain, female pelvic congestion]
R10.2	Pelvic and perineal pain

References

Peer Reviewed Publications:

1. Ascitutto G, Ascitutto KC, Mumme A, Geier B. Pelvic venous incompetence: reflux patterns and treatment results. Eur J Vasc Endovasc Surg. 2009; 38(3):381-386.
2. [Ayechu-Díaz A, Oscoz-Lizarbe M, Pérez-Martínez A, et al. Treatment of adolescent varicocele: Is percutaneous embolization better? Cir Pediatr. 2009; 22\(3\):134-138.](#)
- 2-3. Bachar GN, Belenky A, Greif F, et al. Initial experience with ovarian vein embolization for the treatment of chronic pelvic pain syndrome. Isr Med Assoc J. 2003; 5(12):843-846.
- 3-4. Ball E, Khan KS, Meads C. Does pelvic venous congestion syndrome exist and can it be treated? Acta Obstet Gynecol Scand. 2012; 91(5):525-528.
5. [Bechara CF, Weakley SM, Kougias P, et al. Percutaneous treatment of varicocele with microcoil embolization: Comparison of treatment outcome with laparoscopic varicocelectomy. Vascular. 2009; 17 Suppl 3:S129-S136.](#)
- 4-6. Black CM, Thorpe K, Venrbux A, et al. Research reporting standards for endovascular treatment of pelvic venous insufficiency. J Vasc Interv Radiol. 2010; 21(6):796-803.
- 5-7. Chung MH, Huh CY. Comparison of treatments for pelvic congestion syndrome. Tohoku J Exp Med. 2003; 201(3):131-138.
- 6-8. Cordts PR, Eclavea A, Buckley PJ, et al. Pelvic congestion syndrome: early clinical results after transcatheter ovarian vein embolization. J Vasc Surg. 1998; 28(5):862-868.
- 7-9. Creton D, Hennequin L, Kohler F, Allaert FA. Embolization of symptomatic pelvic veins in women presenting with non-saphenous varicose veins of pelvic origin - three-year follow-up. Eur J Vasc Endovasc Surg. 2007; 34(1):112-117.

[This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.](#)

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

~~Ovarian and Internal Iliac~~ Vein Embolization as a Treatment ~~for~~ Pelvic Congestion Syndrome and Varicocele

8-10. Daniels JP, Champaneria R, Shah L, et al. Effectiveness of embolization or sclerotherapy of pelvic veins for reducing chronic pelvic pain: A systematic review. *J Vasc Interv Radiol.* 2016; 27(10):1478-1486.

11. Favard N, Moulin M, Fauque P, et al. Comparison of three different embolic materials for varicocele embolization: Retrospective study of tolerance, radiation and recurrence rate. *Quant Imaging Med Surg.* 2015; 5(6):806-814.

9-12. Gandini R, Chiocchi M, Konda D, et al. Transcatheter foam sclerotherapy of symptomatic female varicocele with sodium-tetradecyl-sulfate foam. *Cardiovasc Intervent Radiol.* 2008; 31(4):778-784.

10-13. Guirola JA, Sánchez-Ballestin M, Sierre S, et al. A randomized trial of endovascular embolization treatment in pelvic congestion syndrome: fibered platinum coils versus vascular plugs with 1-year clinical outcomes. *J Vasc Interv Radiol.* 2018; 29(1):45-53.

11-14. Hansrani V, Abbas A, Bhandari S, et al. Trans-venous occlusion of incompetent pelvic veins for chronic pelvic pain in women: a systematic review. *Eur J Obstet Gyn Reprod Biol.* 2015; 185:156-163.

12-15. Hobbs JT. Varicose veins arising from the pelvis due to ovarian vein incompetence. *Int J Clin Pract.* 2005; 59(10):1195-1203.

13-16. Hocquelet A, Le Bras Y, Balian E, et al. Evaluation of the efficacy of endovascular treatment of pelvic congestion syndrome. *Diagn Interv Imaging.* 2014; 95(3):301-306.

14-17. Jeanneret C, Beier K, von Weyarn A, Traber J. Pelvic congestion syndrome and left renal compression syndrome - clinical features and therapeutic approaches. *Vasa.* 2016; 45(4):275-282.

15-18. Kies DD, Kim HS. Pelvic congestion syndrome: a review of current diagnostic and minimally invasive treatment modalities. *Phlebology.* 2012; 27(Suppl 1):52-57.

16-19. Kim HS, Malhotra AD, Rowe PC, et al. Embolotherapy for pelvic congestion syndrome: long-term results. *J Vasc Interv Radiol.* 2006; 17(2 Pt 1):289-297.

17-20. Kwon SH, Oh JH, Ko KR, et al. Transcatheter ovarian vein embolization using coils for the treatment of pelvic congestion syndrome. *Cardiovasc Intervent Radiol.* 2007; 30(4):655-661.

18-21. Laborda A, Medrano J, de Blas I, et al. Endovascular treatment of pelvic congestion syndrome: visual analog scale (VAS) long-term follow-up clinical evaluation in 202 patients. *Cardiovasc Intervent Radiol.* 2013; 36(4):1006-1014.

19-22. Mahmoud O, Vikatmaa P, Aho P, et al. Efficacy of endovascular treatment for pelvic congestion syndrome. *J Vasc Surg Venous Lymphat Disord.* 2016; 4(3):355-370.

23. Makris GC, Efthymiou E, Little M, et al. Safety and effectiveness of the different types of embolic materials for the treatment of testicular varicoceles: a systematic review. *Br J Radiol.* 2018; 91(1088):2017-2044.

20-24. Maleux G, Stockx L, Wilms G, Marchal G. Ovarian vein embolization for the treatment of pelvic congestion syndrome: long term technical and clinical results. *J Vasc Interv Radiol.* 2000; 11(7):859-864.

[This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.](#)

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Medical Policy

Ovarian and Internal Iliac Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele

- ~~24-25.~~ Meneses L, Fava M, Diaz P, et al. Embolization of incompetent pelvic veins for the treatment of recurrent varicose veins in lower limbs and pelvic congestion syndrome. *Cardiovasc Intervent Radiol*. 2013; 36(1):128-132.
- ~~22-26.~~ Naoum JJ. Endovascular therapy for pelvic congestion syndrome. *Methodist Deakey Cardiovasc J*. 2009; 5(4):36-38.
- ~~23-27.~~ Nasser F, Cavalcante RN, Affonso BB, et al. Safety, efficacy, and prognostic factors in endovascular treatment of pelvic congestion syndrome. *Int J Gynaecol Obstet*. 2014; 125(1):65-68.
- ~~24-28.~~ O'Brien MT, Gillespie DL. Diagnosis and treatment of the pelvic congestion syndrome. *J Vasc Surg Venous Lymphat Disord*. 2015; 3(1):96-106.
29. Perdikakis E, Fezoulidis I, Tzortzis V, Rountas C. Varicocele embolization: Anatomical variations of the left internal spermatic vein and endovascular treatment with different types of coils. *Diagn Interv Imaging*. 2018; 99(10):599-607.
- ~~25-30.~~ Phillips D, Deipolyi AR, Hesketh RL, et al. Pelvic congestion syndrome: etiology of pain, diagnosis, and clinical management. *J Vasc Interv Radiol*. 2014; 25(5):725-733.
- ~~26-31.~~ Pieri S, Agresti P, Morucci M, de' Medici L. Percutaneous treatment of pelvic congestion syndrome. *Radiol Med (Torino)*. 2003; 105(1-2):76-82.
- ~~27-32.~~ Pyra K, Woźniak S, Roman T, et al. Evaluation of effectiveness of endovascular embolization for the treatment of pelvic congestion syndrome--preliminary study. *Ginekol Pol*. 2015; 86(5):346-351.
- ~~28-33.~~ Sichlau MJ, Yao JS, Vogelzang RL. Transcatheter embolotherapy for the treatment of pelvic congestion syndrome. *Obstet Gynecol*. 1994; 83(5 Pt 2):892-896.
- ~~29-34.~~ Smith PC. The outcome of treatment for pelvic congestion syndrome. *Phlebology*. 2012; 27 Suppl 1:74-77.
- ~~30-35.~~ Stones RW. Pelvic vascular congestion - half a century later. *Clin Obstet Gynecol*. 2003; 46(4):831-836.
- ~~31-36.~~ Tarazov PG, Prozorovakji KV, Ryzhov VK. Pelvic pain syndrome caused by ovarian varices. Treatment of transcatheter embolization. *Acta Radiol*. 1997; 38(6):1023-1025.
- ~~32-37.~~ Tu FF, Hahn D, Steege JF. Pelvic congestion syndrome-associated pelvic pain: a systematic review of diagnosis and management. *Obstet Gynecol Surv*. 2010; 65(5):332-340.
- ~~33-38.~~ Venbrux AC, Chang AH, Kim HS, et al. Pelvic congestion syndrome (pelvic venous incompetence): impact of ovarian and internal iliac vein embolotherapy on menstrual cycle and chronic pelvic pain. *J Vasc Interv Radiol*. 2002; 13(2 Pt 1):171-178.
- ~~34-39.~~ Venbrux AC, Lambert DL. Embolization of the ovarian veins as a treatment for patients with chronic pelvic pain caused by pelvic venous incompetence (pelvic congestion syndrome). *Curr Opin Obstet Gynecol*. 1999; 11(4):395-399.

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

~~Ovarian and Internal Iliac~~ Vein Embolization as a Treatment ~~for~~ Pelvic Congestion Syndrome and Varicocele

Government Agency, Medical Society and Other Authoritative Publications:

1. American Society for Reproductive Medicine; Society for Male Reproduction and Urology. Report on varicocele and infertility: A committee opinion. Fertil Steril. 2014; 102(6):1556-1560. Available at: https://www.asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/for-non-members/report_on_varicocele.pdf. Accessed on July 20, 2020.
- ~~1-2.~~ Angle JF, Siddiqi NH, Wallace MJ, et al.; Society of Interventional Radiology (SIR) Standards of Practice Committee. Quality improvement guidelines for percutaneous transcatheter embolization. 2010. Available at: <http://www.jvir.org/article/S1051-0443%2810%2900648-2/pdf>. Accessed on ~~July 21, 2020~~ December 17, 2019.
- ~~2-3.~~ Centers for Medicare and Medicaid Services. National Coverage Determination for Therapeutic Embolization. NCD #20.28. Effective December 15, 1978. Available at: <http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=52&ncdver=1&DocID=20.28&bc=gAAAAAgAAAAAA%3d%3d&>. Accessed on ~~July 21, 2020~~ December 17, 2019.
- ~~3-4.~~ Cheong YC, Smotra G, Williams AC. Non-surgical interventions for the management of chronic pelvic pain. Cochrane Database Syst Rev. 2014; (3):CD008797. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008797.pub2/full>. Accessed on ~~July 21, 2020~~ December 17, 2019.
- ~~4-5.~~ Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011; 53(5 Suppl):2S-48S.
- ~~5-6.~~ Society of Interventional Radiology (SIR). Patient Information Sheet on Chronic Pelvic Pain in Women and Pelvic Congestion Syndrome. 2014. Available at: ~~<https://www.sirweb.org/patient-center/pelvic-congestion-syndrome-chronic-pelvic-pain/>~~ <https://www.sirweb.org/patient-center/pelvic-venous-disease/>. Accessed on ~~July 21, 2020~~ December 17, 2019.

Index

- Embolization Therapy for Pelvic Congestion Syndrome
- Internal Iliac and Ovarian Vein Embolization as a Treatment of Pelvic Congestion Syndrome
- Ovarian and Internal Iliac Vein Embolization as a Treatment of Pelvic Congestion Syndrome
- Pelvic Congestion Syndrome
- Pelvic Pain – Embolization Therapy for Pelvic Congestion Syndrome

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

~~Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.~~

~~No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.~~

~~Ovarian and Internal Iliac~~ Vein Embolization as a Treatment ~~for~~ Pelvic Congestion Syndrome and Varicocele

Testicular (gonadal) Vein Embolization
Varicocele

Vein Embolization as a Treatment of Pelvic Congestion Syndrome

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Document History

Status	Date	Action
<u>Revised</u>	<u>11/05/2020</u>	<u>Medical Policy & Technology Assessment Committee (MPTAC) review. An INV and NMN statement for embolization for varicocele has been added to the Position Statement section. The Scope, Rationale, Definitions, References and Index sections were updated. The title has changed from: Ovarian and Internal Iliac Vein Embolization as a Treatment of Pelvic Congestion Syndrome to: Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele. Updated Coding section; added ICD-10-CM I86.1 and ICD-10-PCS codes.</u>
Reviewed	02/20/2020	Medical Policy & Technology Assessment Committee (MPTAC) review. References were updated.
Reviewed	03/21/2019	MPTAC review. References were updated.
Reviewed	03/22/2018	MPTAC review. The document header wording was updated from “Current Effective Date” to “Publish Date.” References were updated.
Reviewed	05/04/2017	MPTAC review. The Rationale and References were updated.
Reviewed	05/05/2016	MPTAC review. Rationale and References were updated. Removed ICD-9 codes from Coding section.
Reviewed	05/07/2015	MPTAC review. References were updated.
Reviewed	05/15/2014	MPTAC review. The Rationale and References were updated.
	01/01/2014	Updated Coding section with 01/01/2014 CPT changes; removed 37204 deleted 12/31/2013, and 75894.
Reviewed	05/09/2013	MPTAC review. The Rationale, Definitions and References were updated.
Reviewed	05/10/2012	MPTAC review. The Rationale and References were updated.
Reviewed	05/19/2011	MPTAC review. References were updated.

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

~~Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.~~

~~No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.~~

Ovarian and Internal Iliac Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele

Reviewed	05/13/2010	MPTAC review. References were updated.
Reviewed	05/21/2009	MPTAC review. The Rationale and References were updated.
Reviewed	05/15/2008	MPTAC review. Description clarified by removing surgical ligation. References updated.
	02/21/2008	The phrase "investigational/not medically necessary" was clarified to read "investigational and not medically necessary." This change was approved at the November 29, 2007 MPTAC meeting.
Reviewed	05/17/2007	MPTAC review. References updated.
Reviewed	06/08/2006	MPTAC review. The Rationale and References were updated.
	11/22/2005	Added reference for Centers for Medicare and Medicaid Services (CMS) – National Coverage Determination (NCD).
Revised	07/14/2005	MPTAC review. Revision based on Pre-merger Anthem and Pre-merger WellPoint Harmonization.

Pre-Merger Organizations	Last Review Date	Document Number	Title
Anthem, Inc.	10/28/2004	SURG.00062	Ovarian and Internal Iliac Vein Embolization as a Treatment of Pelvic Congestion Syndrome
WellPoint Health Networks, Inc.	06/24/2004	3.09.09	Ovarian and Internal Iliac Vein Embolization as a Treatment of Pelvic Congestion Syndrome

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.